DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
NTRA logo

Natera, Inc. Stock Price

NasdaqGS:NTRA Community·US$47.4b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 61 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

NTRA Share Price Performance

US$328.93
156.77 (91.06%)
​
US$280.00
Fair Value
US$328.93
156.77 (91.06%)
17.5% overvalued intrinsic discount
US$280.00
Fair Value
Price US$328.93
AnalystLowTarget US$280.00
AnalystConsensusTarget US$282.14
AnalystHighTarget US$375.00
Thu, 3 Sep 26
Fair ValueUS$280.00
Share Pricen/a

NTRA Community Narratives

AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$280 17.5% overvalued intrinsic discount

Tightening US And European Regulations Will Stunt Diagnostic Developments

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$282.14 16.6% overvalued intrinsic discount

Clinical Advances and AI Will Drive Expansion Into New Diagnostic Markets

1users have liked this narrative
0users have commented on this narrative
17users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$375 12.3% undervalued intrinsic discount

Personalized Medicine And AI Will Redefine Diagnostics

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
NTRA logo
Natera
17.5% overvalued intrinsic discount

Tightening US And European Regulations Will Stunt Diagnostic Developments

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 3 Sep
Read Narrative
NTRA logo
Natera
12.3% undervalued intrinsic discount

Personalized Medicine And AI Will Redefine Diagnostics

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 18 Aug
Read Narrative
NTRA logo
Natera
16.6% overvalued intrinsic discount

Clinical Advances and AI Will Drive Expansion Into New Diagnostic Markets

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 20 Jul
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystLowTarget
NTRA logo

NTRA: Elevated Expectations Around MRD Adoption Will Pressure 2026 Catalyst Payoff

Fair Value: US$280 17.5% overvalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
NTRA logo

NTRA: Guideline MRD Tailwinds Will Drive Future Oncology Volume Upside

Fair Value: US$375 12.3% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
NTRA logo

NTRA: Guideline And Regulatory Tailwinds Will Support Balanced 2026 MRD Outlook

Fair Value: US$282.14 16.6% overvalued intrinsic discount
17 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Flawless balance sheet with reasonable growth potential.

0 Risks
3 Rewards
View Full Analysis

Natera, Inc. Key Details

US$2.7b

Revenue

US$941.2m

Cost of Revenue

US$1.8b

Gross Profit

US$2.0b

Other Expenses

-US$192.3m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-1.33
65.23%
-7.11%
4.4%
View Full Analysis

About NTRA

Founded
2003
Employees
6138
CEO
Steven Chapman
WebsiteView website
www.natera.com

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

Recent NTRA News & Updates

User avatar
Narrative Update • Sep 03

NTRA: Elevated Expectations Around MRD Adoption Will Pressure 2026 Catalyst Payoff

The analyst price target for Natera has been revised higher from $206.81 to $280.00 as analysts incorporate Q2 report takeaways, stronger expectations around Signatera performance, oncology and MRD volume trends, and improving profitability into their models. Analyst Commentary Recent Street research on Natera clusters around a constructive view of the core oncology and minimal residual disease, or MRD, opportunity, while also highlighting valuation sensitivity and execution risk.

Recent updates

No updates

Natera, Inc. Competitors

MRK logo

Merck

Symbol: NYSE:MRK
Market cap: US$355.1b
TMO logo

Thermo Fisher Scientific

Symbol: NYSE:TMO
Market cap: US$225.5b
AMGN logo

Amgen

Symbol: NasdaqGS:AMGN
Market cap: US$204.0b
GILD logo

Gilead Sciences

Symbol: NasdaqGS:GILD
Market cap: US$178.2b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide